IRVINE, Calif.--(BUSINESS WIRE)--March 6, 2006--Allergan, Inc. (NYSE:AGN) today announced that it is extending the expiration date of its exchange offer for all outstanding shares of common stock of Inamed Corporation (NASDAQ:IMDC), as U.S. antitrust approval of the Inamed acquisition has not yet been received. The U.S. antitrust approval by the Federal Trade Commission (FTC) is the only remaining antitrust clearance required to complete the Inamed acquisition.
